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Abstract
Naturally acquired humoral immunity to the malarial parasite Plasmodium falciparum can protect against disease, although
the precise mechanisms remain unclear. Although antibody levels can be measured by ELISA, few studies have investigated
functional antibody assays in relation to clinical outcomes. In this study we applied a recently developed functional assay of
antibody-mediated opsonisation of merozoites, to plasma samples from a longitudinal cohort study conducted in a malaria
endemic region of Papua New Guinea (PNG). Phagocytic activity was quantified by flow cytometry using a standardized and
high-throughput protocol, and was subsequently evaluated for association with protection from clinical malaria and high-
density parasitemia. Opsonising antibody responses were found to: i) increase with age, ii) be enhanced by concurrent
infection, and iii) correlate with protection from clinical episodes and high-density parasitemia. Stronger protective
associations were observed in individuals with no detectable parasitemia at baseline. This study presents the first evidence
for merozoite phagocytosis as a correlate of acquired immunity and clinical protection against P. falciparum malaria.
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Introduction
Malaria is caused by the protozoan parasites Plasmodium spp., of
which Plasmodium falciparum is responsible for most of the mortality
and morbidity associated with the disease worldwide. There have
been major gains in malaria control in endemic countries since
2000, due to measures such as long-lasting insecticidal nets, indoor
residual spraying, rapid diagnostic testing, and access to
artemisinin combination therapy. While incidence and mortality
have declined, malaria still causes 216 million cases and 655,000
deaths per year, predominantly in young children and pregnant
women (WHO 2011 report). In addition there are increasing
reports of emerging artemisinin drug and insecticide resistance in
some regions [1,2]. Therefore, there remains an urgent need for
vaccines to enhance control and contribute to the elimination of
malaria [3].
The rationale for vaccine development arose from observations
of immunity acquired through natural exposure to malaria.
Individuals living in malaria-endemic areas can develop both
humoral and cell mediated immunity over time and with exposure
(reviewed in [4]). Although this immunity is non-sterilising, it
results in reduced parasite densities and protection from life-
threatening clinical disease. In particular, transfer of c-globulin
from immune African adults to non-immune children alleviated
severe disease [5,6], which demonstrates the importance of
antibodies for clinical protection against P. falciparum malaria.
Humoral responses are mounted against pre-erythrocytic,
sexual and asexual blood stages of the malaria lifecycle [4,7,8].
In particular, merozoite surface antigens are strongly targeted by
naturally acquired humoral immunity and hence could serve as
targets for vaccine development. At present, the leading blood-
stage vaccine candidates with some reported protective efficacy in
clinical trials target merozoite proteins [9,10]. Additional mero-
zoite antigens are currently being investigated as vaccine
candidates, and methods for the pre-clinical prioritization of
targets are needed. A number of studies have investigated
associations between clinical immunity and ELISA-based mea-
sures of antibodies to merozoite surface antigens. While antibodies
to some antigens such as the MSP3 C-terminus have consistently
been associated with protection [11], studies of other vaccine
candidates such as AMA-1 and MSP-2 have produced conflicting
results [12–15]. Serology does not measure affinity, avidity,
glycosylation or Fc region status of antibodies, or potentially
differing functions of anti-merozoite antibodies such as invasion
inhibition and opsonisation. Thus, there is a need to utilise assays
that measure functionally protective properties of antibodies.
Opsonising antibodies against merozoites require interactions
with neutrophils or monocytes to trigger an anti-parasitic response.
Functional in vitro assays used to study opsonisation of merozoites
include antibody dependent cellular inhibition (ADCI), respiratory
burst and phagocytosis assays [16–18] ADCI and respiratory burst
require the release of soluble mediators which kill parasites or
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inhibit their growth, while merozoite phagocytosis involves the
active removal of merozoites by phagocytic cells following schizont
rupture. While the anti-parasitic effector mechanism measured
differs between ADCI, respiratory burst and phagocytosis assays,
cytophilic IgG and Fcc receptor-interactions (FccR) on phagocytes
are conserved. This suggests cytophilic antibodies may be able to
interact with both monocytes and neutrophils and result in the
destruction of opsonised merozoites via multiple effector mecha-
nisms.
To date, merozoite opsonisation assays have been inadequately
applied to the study of naturally acquired immunity and disease
risk. The ADCI assay has not been rigorously validated for
associations with clinical protection in longitudinal cohorts or
otherwise, nor has the soluble factor responsible for parasite killing
been identified. Antibody-dependent respiratory burst against
merozoites has recently been shown to correlate with protection
from clinical episodes [19], however the role of high reactive
oxygen species (ROS) in malaria is unclear, as ROS production
has also been linked to malarial anaemia in children [20].
Antibodies promoting merozoite phagocytosis increase gradually
with age, and are higher in individuals resistant to high-density
parasitemia [21]. Merozoite surface protein 3 (MSP3) Long
Synthetic Peptide, and the MSP3/GLURP fusion protein GMZ2
are candidate vaccines under development. Antibodies to these
merozoite vaccine antigens have no direct growth inhibitory
function, but produce an ADCI response in vitro in the presence of
monocytes [22,23]. Although MSP3 Long Synthetic peptide and
GMZ2 vaccines will require phagocyte effector functions to be
effective, and have already progressed to clinical trials [10,24], the
potential protective effect of anti-merozoite functional antibodies
in general remains to be characterised.
To further investigate the contribution of merozoite opsonising
antibodies to naturally acquired immunity to malaria, we applied a
recently developed merozoite phagocytosis assay [25] to a
longitudinal treatment-reinfection study of semi-immune Papua
New Guinean (PNG) children [26]. The results presented here
constitute the first demonstration of phagocytosis-inducing opso-
nising antibodies as a correlate of clinical immunity against P.
falciparum malaria.
Materials and Methods
Study Population and Ethics Statement
Details of the cohort were described elsewhere [26]. In brief,
plasma samples were obtained from a prospective treatment-
reinfection study of children aged 5–14 years from Madang
Province on the north coast of PNG. The presence of P. falciparum
infection was determined by post-polymerase chain reaction (PCR)
ligase detection reaction-florescent microsphere assay (LDR-FMA)
and light microscopy (LM), with detection thresholds of approx-
imately .0.3 parasite/mL and .40parasite/mL, respectively [27].
Baseline clinical observations and peripheral blood samples were
collected at enrolment. Following enrolment, all participants
received 7 days of oral artesunate treatment to clear any current
malarial infections. The cohort was followed for 6 months, with
symptomatic illness and parasitemia identified with fortnightly
follow-ups (active surveillance) and when a child presented with
symptoms at the local Mugil Health Centre (passive surveillance).
The study was approved by the Medical Research Advisory
Committee (MRAC), Papua New Guinea Ministry of Health, The
Walter and Eliza Hall Institute Human Research Ethics Com-
mittee and the institutional review board of the Veteran’s Affairs
Medical Center (Cleveland, Ohio). Written consent was obtained
from parents/guardians of all participants.
Plasma Samples
A venous blood sample was collected at enrolment into
heparinised collection tubes, and plasma collected and stored at
280uC. Positive control sera was collected from adults within the
Madang province, and negative control sera from malaria naı¨ve
anonymous Australian blood donors. For use in phagocytosis
assays, plasma samples were serially diluted to a 1/2000 dilution in
THP-1 medium.
THP-1 Monocyte Cell Line
The human monocytic cell line THP-1 (TIB-202, American
Type Culture Collection, ATCC) was maintained in RPMI-1640
supplemented with 10% foetal bovine serum (FBS) and 55 mM 2-
mercapthoethanol (THP-1 medium), and maintained below a
density of 56105 cells/mL.
Plasmodium falciparum 3D7 Culture and Merozoite
Isolation
P. falciparum 3D7 parasites were cultured at 4% hematocrit in
RPMI-1640 supplemented with 25 mg/mL HEPES, 2 mg/mL
sodium bicarbonate, and 10% pooled human serum (parasite
medium). Cultures were maintained at 37uC in an atmosphere of
5% CO2, 1% O2 and 94% N2, and synchronized using 5%
sorbitol. Late-stage parasites (36–40 hr) were isolated (.95%
purity) from uninfected RBCs with a MAC magnet separation
column (Miltenyi Biotech). Schizonts were treated with 10 mM
E64 (Sigma-Aldrich) for up to 10 hours, and merozoites isolated as
previously described [25].
Phagocytosis Assay
Phagocytosis assays were performed as previously described
[25], with minor adjustments. In brief, 1.26106 EtBr-stained
merozoites in 150 mL were mixed with 10 mL of diluted plasma
samples, and aliquots of 50 mL were transferred to FBS-coated 96-
well U-bottom plates containing 16105 THP-1 cells to make a
final volume of 200 mL per well. Each sample was tested in
triplicate. Plates were incubated for 40 minutes at 37uC in 5%
CO2 humidified incubator, followed by two washes in ice-cold
PBS to arrest phagocytosis. Samples were fixed in 2% parafor-
maldehyde (PFA), and 20,000 events were acquired using a
FACSCalibur flow cytometer (BD Bioscience). Data analysis was
performed using FlowJo software. Viable cells were gated by
forward and side scatter, and phagocytosis positive gates were
determined using THP-1 cells alone. Percentage phagocytosis
refers to the percentage of EtBr positive cells with immune plasma
minus the percentage of positive cells with non-immune plasma.
Statistical Analysis
Statistical analysis was performed using STATA 9.2 (STATA-
Corp, College Station, Texas, USA). Differences in %phagocytosis
between categorical variables were assessed using two-sample
Wilcoxon rank sum test or Kruskal-Wallis tests. For analysis of
associations with clinical outcomes, children with no detectable P.
falciparum parasitemia by PCR or LM during follow up were
regarded as non-exposed, and as such 5% of children were
excluded from analysis. In addition, children that failed to clear
infections following treatment at baseline(n = 12) as determined by
msp2 genotyping, were also excluded from analysis. A range of
demographic and clinical variables were assessed as potential
confounders. The median age of individuals was 9.3 years (range,
5–14; interquartile range, 8.1–10.3 years). A range of age groups
was investigated, and two groups (,9 years and $9 years) were
most informative in concordance with previous investigations with
Merozoite Opsonising Antibodies and Immunity
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this cohort [14,26,28–31]. Location of residence (attendance at
Mugil school and living 1 km from the seaboard) were also
included as known confounding variables [26].
To describe optimally associations between opsonising antibody
responses and subsequent episodes of P. falciparum infection and
clinical episodes, phagocytosis responses were rescaled (%phago-
cytosis20) to generate 4 groups reflecting 20% increases (range,
original 5–79%; re-scaled: 0.25–3.95). Poisson regression modeling
produced incidence rate ratios (IRR) for the incidence of clinical
malaria episodes or high-density parasitemia (.5000parasites/
mL). Clinical malaria was defined as a measured fever (axillary
temperature #37.5uC) or history of febrile illness during the
48hours preceding examination in conjunction with P. falciparum
infection of any density as measured by light microscopy. Eighty
percent of the 100 individuals that experienced at least 1 clinical
episode had an infection density of greater than 5000 parasites/
mL. Seventeen percent of the 92 individuals with an infection of
.5000 parasites/mL did not present with clinical symptoms. Cox
proportional hazards modeling was used to calculate hazard ratios
(HR) for time to first P. falciparum infection by PCR, light
microscopy, and time to first infection of .500 and .5000
parasites/mL. Although some children had multiple episodes of
parasitemia or malaria, HR analysis included time to first re-
infection or first clinical episode only.
Results
Opsonising Antibody Responses are Robust and
Reproducible
We recently developed a merozoite phagocytosis assay which
measures FccR-dependent phagocytosis responses [25]. When this
assay was applied to plasma samples from 198 PNG children, the
percentage of THP-1 cells that had phagocytosed merozoites
ranged from 5–79% (representative responses in figure 1A). Low
background responses below five percent EtBr positive THP-1
cells were observed for non-exposed Australian control plasma,
indicating that the assay requires antigen-specific opsonising
antibodies. Plasma samples were tested in triplicate, and opsonis-
ing responses were measured in three separate experiments
(figure 1B). All experiments showed highly correlated measure-
ments (figure 1C, Spearman correlation coefficients; expt1 vs.
expt2 rs = 0.91, p,0.0001; expt1 vs. expt3 rs = 0.93 p,0.0001)
and highly concordant data (figure 1D, Bland-Altman test; expt1
vs. expt2 bias = 5.39, sd = 8.73; expt1 vs. expt3 bias = 1.79, sd
= 9.3). Therefore, the mean of the three experiments was used for
subsequent analyses. Across the 198 plasma samples tested, a
spectrum of responses was measured (figure 1e), indicating the
assay was of sufficient sensitivity to resolve small differences in
opsonising antibody levels between individuals in the cohort.
Age and Parasitemia at Baseline Strongly Influence
Opsonising Antibody Responses
Opsonising antibody responses were analysed in relation to a
range of clinical and demographic variables. Consistent with
previous studies of this cohort, responses were influenced by the
age of individuals and the presence of P. falciparum parasites at the
time of blood sampling [14,26]. Consistent with previous studies
[14,26,29,30], age was most informative when assessed as a binary
variable of ,9 and $9 years of age. The older age group showed
higher opsonising antibody responses (median, 54.8; IQR, 40.7–
66.9) than younger children (median, 46.2; IQR, 27.9–64.7; p
= 0.01)(figure 2A). As the plasma samples were collected prior to
anti-malarial treatment, 68% of individuals had P.falciparum
infection at baseline as measured by post-PCR LDR-FMA (termed
PCR). Parasite positive individuals at baseline displayed increased
opsonising responses (median, 58.7; IQR, 44.2–66.9) than those
without concurrent infection (median, 40.1; IQR, 24.5–55.1; p
= 0.0001) (figure 2B). When individuals were stratified by age and
by parasitemia at baseline, higher opsonising antibody responses in
the presence of parasites were only significant in children,9 years
(figure 2C). Similar patterns were observed when responses were
stratified by the presence or absence of light microscopy positive
infections (data not shown). In addition, no differences in
opsonising antibodies were observed in PCR positive individuals
at baseline for infections above or below the detection limit of
light-microscopy (data not shown). Therefore, PCR+ infections
showed significant boosting of opsonising antibody responses,
particularly in young children.
Opsonising Antibodies are Associated with Protection
from Clinical Malaria and High-density Parasitemia
As highly heterogeneous opsonising antibody responses were
observed we investigated whether responses were associated with
clinical outcomes and risk of clinical malaria. Higher opsonising
antibody responses were observed in individuals who did not
experience a clinical episode (median, 56.1; IQR, 39.9–67.0) than
in individuals that experienced any number of clinical episodes
(median, 49.8; IQR, 31.7–64.0; p = 0.04). As up to 3 clinical
episodes were observed for some individuals, we investigated
whether the level of opsonising antibodies differed between those
that experienced none, 1, 2 or 3 clinical episodes during follow-up.
In addition, we assessed whether baseline parasitaemia influenced
the level of opsonising antibody within these clinical groups. When
individuals with no detectable parasitemia at baseline were
investigated, lower phagocytic responses were observed in
individuals who experienced multiple clinical episodes, than in
individuals who experienced none or one clinical episode during
follow-up (figure 3). Individuals with concurrent infection at
baseline showed no differences in phagocytosis responses across
the range of clinical episodes.
To investigate the association between opsonising antibodies
and risk of clinical disease, % phagocytosis data was rescaled to
represent 4 groups, each a 20% increment in phagocytosis
responses. By Poisson regression analysis, %phagocytosis20 was
associated with a reduced risk of clinical malaria (IRR 0.81;
95%CI, 0.68–0.95; p = 0.01). Interestingly, a significant and
stronger association with reduced risk of clinical disease was
observed for individuals with no detectable parasitemia at baseline
(IRR 0.62; 95%CI, 0.46–0.83; p = 0.002), while parasite PCR+
individuals showed no significant association (IRR 0.94; 95%CI,
0.74–1.173; p = 0.56). The lack of protective association for
infection at baseline was maintained when individuals were
stratified into PCR+LM2 or PCR+LM+ infections at baseline
(data not shown). Incidence rate ratios in PCR- individuals
remained significant after adjustment for age and location of
residence (figure 4). This is equivalent to an age and location-
adjusted 38% reduction in risk of clinical disease with each 20%
increase in phagocytosis responses.
We then investigated whether opsonising responses were
associated with reduced risk of acquiring new P. falciparum
infections of varying parasite densities. Opsonising antibody
responses were not associated with a reduced time to re-infection
by PCR, LM, or moderate density infection (.500 parasites/mL).
However, a reduced risk of acquiring a high-density infection
(.5000 parasites/mL) was observed for opsonising responses (HR,
0.75; 95% CI, 0.60–0.95; p = 0.018). This association was
observed without stratification by PCR+ infection, and was
unaltered by adjustment for age and location (HR, 0.73; 95%
Merozoite Opsonising Antibodies and Immunity
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CI, 0.54–0.99; p = 0.04) (figure 5). This equates to an age and
location-adjusted 27% reduction in risk of high-density parasit-
emia with each 20% increase in phagocytosis responses. A slightly
lower risk of high-density infection in individuals with no
detectable parasitemia at baseline than in those with concurrent
infection was observed, but was not significant (data not shown).
Discussion
Merozoite invasion has been proposed to occur within seconds
following schizont rupture [32], casting doubt on the ability of
merozoite phagocytosis to be an effective anti-parasite mechanism.
However, a new technique for purifying viable merozoites has
uncovered the ability of merozoites to remain invasive for ten
minutes after mechanical rupture of schizonts [33]. This provides
Figure 1. Phagocytosis responses are robust and reproducible. A) EtBr stained merozoites were incubated with plasma, and were added to
THP-1 cells. EtBr fluorescence was determined by flow cytometry, and THP-1 cells gated by forward and side scatter. Representative flow cytometry
plots show EtBr positive events with i) a pool of non-exposed Australian plasma ii) plasma from an exposed PNG donor that resulted in a high
response and iii) PNG donor plasma that resulted in low responses. B) Percentage phagocytosis was calculated for 198 plasma samples from PNG
children in three independent experiments. C) Interassay comparisons as determined by Spearman correlation (expt1 vs. expt2 rs = 0.91, p,0.0001;
expt1 vs. expt3 rs = 0.93 p,0.0001) and by D) Bland-Altman test (expt1 vs. expt2 bias = 5.39, sd = 8.73; expt1 vs. expt3 bias = 1.79, sd = 9.3). E) The
average % phagocytosis responses from three experiments were ranked by magnitude.
doi:10.1371/journal.pone.0074627.g001
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sufficient time for antibodies to opsonise merozoites, and for these
merozoites to encounter monocytes or neutrophils in circulation,
or macrophages as they pass through the spleen. Therefore,
merozoite phagocytosis may represent a significant mechanism
contributing to anti-parasite immunity. This is further supported
by this study where we newly describe an association between
opsonising antibodies leading to merozoite phagocytosis and
protection from clinical malaria and high-density parasitemia.
These associations remained significant after adjustment for
known confounders of age and location of residence. Opsonising
antibodies increased with age, but were strongly influenced by
concurrent infection. Phagocytic responses were reduced in
individuals susceptible to multiple clinical episodes, which suggests
that steady state levels of opsonising antibody are a suitable
predictor of immune status in children.
Limited data exists on the maintenance of P. falciparum
antibodies in children, or boosting of immune responses in
response to infection. We found that individuals infected with P.
falciparum at baseline showed increased opsonising antibody levels,
an effect observed more strongly in younger children. Fifty per
cent of the baseline PCR+ individuals were below the detection
limits of light microscopy, which indicates low-density infections
(,40 parasites/mL) are enough to boost antibody responses.
However, antibody responses to P. falciparum antigens are believed
to have a dynamic and short-lived profile, particularly in young
children or non-immune young adults that are unable to mount an
efficient anti-malaria B cell memory response [34–36]. Longitu-
dinal studies in African children report the half-lives of merozoite
specific antibodies range between 6 to 52 days following malaria
infection, with younger children displaying the most rapid decay of
antibody responses [34,36]. In this context it is reasonable to
propose that the increased opsonising responses detected in
individuals with concurrent infections at baseline reflect short-
lived (and presumable low affinity) antibodies elicited in response
to those infections.
Interestingly, no association with reduced incidence of clinical
episodes and opsonising antibody responses was observed in
children who were parasitaemic at baseline. Asymptomatic
carriage of P. falciparum, as detectible on thick smear by light
microscopy, has been reported to confer some protection from
clinical episodes [37]. In this study we observed no difference in
the level of opsonising antibody or risk of clinical disease in those
with light-microscopy positive infections compared to infections
that were only PCR positive. In contrast, merozoite opsonising
antibody responses in children without parasitaemia at baseline
were associated with reduced risk of clinical disease, suggesting a
longer-lived immunological status that might more reliably reflect
naturally acquired immunity. These findings emphasize the
importance of adjusting for baseline parasitological status in
investigating correlates of acquired humoral immunity to malaria.
Monocytes purified from immune individuals have been shown
to phagocytose merozoites more efficiently than monocytes from
non-immune individuals; indicating that monocytes may also be
primed for merozoite phagocytosis in vivo [17]. Although we did
not assess the endogenous monocyte phagocytic capacity in
individuals of this study, we demonstrated that opsonising
antibody responses were significantly associated with reduced
incidence of clinical episodes. While these results do not establish a
causative link with protection from clinical disease, mouse models
of malaria strongly support the role for anti-merozoite opsonising
antibodies. Human monoclonal antibodies to P. falciparum MSP119
failed to transfer immunity to mice unless recipients were
transgenic for the human FccRI receptor [38], indicating the
importance of phagocyte effector functions for blood stage
humoral immunity. Initiation of ADCI requires engagement of
FccRII and FccRIII [39], while cross-linking of FccRI is required
for respiratory burst [19]. The Fc receptors involved in merozoite
phagocytosis remain undefined, but likely mirror the need for
FccRI, and to a lesser extent FccRII during phagocytosis of P.
falciparum trophozoites [40] and other pathogens [41,42]. This
implicates phagocytosis, and/or respiratory burst, as the likely
effector mechanisms following passive transfer of humoral
immunity. ROS release has been considered a downstream event
following phagocytosis of opsonised merozoites, however links
between the two cellular responses are unclear.
In this same cohort, we have previously shown that in vitro IFNc
output from peripheral blood mononuclear cells in response to
malaria parasites provides a correlate of cellular immunity to P.
falciparum [43,44]. IFNc potently enhances FcR-mediated mono-
cyte/macrophage phagocytosis and ROS, and may function to
promote opsonising immunity to malaria. Cell populations
capable of producing IFNc in response to malaria include cd
Figure 2. Age and concurrent parasitemia influence opsonising
antibody responses. Comparison of opsonising antibody responses
in children that were stratified; A) into two age groups of #9 years and
.9 years; B) on the basis of PCR detectable P. falciparum infection at
baseline; and C) by both age and infection at baseline. Data are plotted
as box-and-whisker plots showing medians and interquartile ranges.
Error bars show 95% confidence intervals. Statistical significance was
determined by Kruskal-Wallis test (1 d.f.).
doi:10.1371/journal.pone.0074627.g002
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Tcells, NK cells, CD1-restricted NKT cells [45,46] and conven-
tional CD4 and CD8 T cells [47], indicating a wide range of
potential cellular interactions across the innate and adaptive
immune systems capable of promoting phagocytosis and parasite
killing in concert with opsonising antibodies.
Currently, there are vaccines under development that are
designed to induce a cytophilic antibody profile and promote
FccR-mediated phagocyte responses [10,24]. This study describes
an association between opsonising antibody responses to P.
falciparum merozoites with protection from clinical disease and
high-density parasitemia, measured in an FccR-dependent in vitro
assay. ADCI and respiratory burst assays require the use of
primary cells, which may be a factor responsible for the inter-
experimental variability and reproducibility issues associated with
such assays. The use of a monocytic cell line in this study enabled a
highly reproducible readout, and the associations with clinical
outcomes supports the application of this functional assay of anti-
merozoite immunity to larger cohorts and vaccine trials. The
Figure 3. High opsonising responses in individuals protected from clinical malaria, only in the absence of baseline infection.
Phagocytic responses were stratified on the basis of PCR detectable P. falciparum infection at baseline (white bars represent PCR- individuals and grey
bars PCR+ individuals) and the number of clinical episodes (fever $37.5uC with parasitemia) during follow-up. Statistical significance was determined
by Kruskal-Wallis test (3 d.f., indicated by text) and by Wilcoxon rank sum test (indicated by asterisks, *p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0074627.g003
Figure 4. Incidence of clinical malaria episodes during follow-
up relative to opsonising antibody responses. Incidence rate
ratios (IRR) for %phagocytosis20 and the incidence of clinical malaria
episodes over the 6 months of follow up were calculated for all
individuals and after stratification based on PCR+ P. falciparum infection
at baseline. Values represent un-adjusted IRR (filled circle) and adjusted
IRR (age and location adjusted, open squares) 695% confidence
intervals, and asterisks mark significant associations (* p,0.05,**
p,0.01).
doi:10.1371/journal.pone.0074627.g004
Figure 5. Associations between opsonising antibodies and risk
of acquiring P. falciparum infections of varying density. Hazard
ratios (HR) were generated to assess associations with %phagocytosis20
and time to first PCR detectable, light microscopy (LM) detectable,
$500 parasites/mL, and$5000 parasites/mL infections. Observation time
was 6 months, and analysis based on first infection only. Values
represent un-adjusted HR (filled circle) and adjusted HR (age and
location adjusted, open squares) 695% confidence intervals, and
asterisks mark significant associations (* p,0.05).
doi:10.1371/journal.pone.0074627.g005
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clinical protection observed in this study suggests merozoite
phagocytosis may be an important anti-parasitic effector mecha-
nism of natural acquired immunity to P. falciparum malaria, thus
further investigation into the protective antigenic targets of this
response is warranted.
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